இந்தியா மருந்து தயாரிப்பு உலகளாவிய அங்கீகாரத்தை விரிவு படுத்துகிறது.

India is expanding the global recognition of its pharmacopeia, which now includes 18 nations, by building support through technical diplomacy and regulatory collaborations. This initiative aims to reduce export costs and make Indian medicines more affordable, particularly in developing nations. A significant milestone is India's permanent membership in the Pharmacopoeial Discussion Group (PDG), alongside the US, European, and Japanese pharmacopoeias. 

• Expanding acceptance: India is actively working to gain wider acceptance for the Indian Pharmacopoeia (IP).
  • The initiative has yielded results, with 17 countries already recognizing the IP, including 12 in the last two years, says a report in Business Standard.
  • Ethiopia is currently evaluating IP standards, with a recommendation expected soon.
  • Nicaragua became the first Spanish-speaking nation to recognize the Indian Pharmacopoeia standards, notes the Indian Pharmacopoeia Commission.
• Strategic engagement: India's efforts include:
  • Technical diplomacy and regulatory collaborations.
  • On-ground audits to ensure standards.
  • Organizing events like Policy Makers' Fora with participation from many countries, primarily from the Global South.
• Benefits of wider acceptance:
  • Reduced export costs for Indian pharmaceuticals.
  • Increased affordability of Indian drugs for other nations, especially developing ones.
• Harmonizing global standards:
  • India became a permanent member of the Pharmacopoeial Discussion Group (PDG) in September 2023.
  • This places the IP alongside the pharmacopoeias of the US, Europe, and Japan, which is a crucial step for harmonizing global standards.